HomeCompareDCPH vs ORCC

DCPH vs ORCC: Dividend Comparison 2026

DCPH yields 7.82% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DCPH wins by $12.1K in total portfolio value
10 years
DCPH
DCPH
● Live price
7.82%
Share price
$25.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.6K
Annual income
$1,282.05
Full DCPH calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — DCPH vs ORCC

📍 DCPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDCPHORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DCPH + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DCPH pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DCPH
Annual income on $10K today (after 15% tax)
$664.32/yr
After 10yr DRIP, annual income (after tax)
$1,089.74/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, DCPH beats the other by $1,088.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DCPH + ORCC for your $10,000?

DCPH: 50%ORCC: 50%
100% ORCC50/50100% DCPH
Portfolio after 10yr
$27.5K
Annual income
$641.54/yr
Blended yield
2.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on DCPH right now

DCPH
Analyst Ratings
13
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$26.32
+2.9% upside vs current
Range: $25.00 — $30.00
Altman Z
7.4
Piotroski
3/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DCPH buys
0
ORCC buys
0
No recent congressional trades found for DCPH or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDCPHORCC
Forward yield7.82%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$33.6K$21.4K
Annual income after 10y$1,282.05$1.04
Total dividends collected$10.4K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$26.32$16.00

Year-by-year: DCPH vs ORCC ($10,000, DRIP)

YearDCPH PortfolioDCPH Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$11,482$781.56$11,190$489.61+$292.00DCPH
2$13,124$838.64$12,229$256.01+$895.00DCPH
3$14,938$895.89$13,216$130.74+$1.7KDCPH
4$16,937$953.05$14,207$66.02+$2.7KDCPH
5$19,133$1,009.87$15,234$33.17+$3.9KDCPH
6$21,538$1,066.15$16,317$16.62+$5.2KDCPH
7$24,167$1,121.67$17,468$8.32+$6.7KDCPH
8$27,035$1,176.26$18,695$4.16+$8.3KDCPH
9$30,158$1,229.77$20,006$2.08+$10.2KDCPH
10$33,551$1,282.05$21,407$1.04+$12.1KDCPH

DCPH vs ORCC: Complete Analysis 2026

DCPHStock

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Full DCPH Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this DCPH vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DCPH vs SCHDDCPH vs JEPIDCPH vs ODCPH vs KODCPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.